PNC Financial Services Group
PRLD icon

PNC Financial Services Group’s Prelude Therapeutics PRLD Stock Holding History

PNC Financial Services Group’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Hold
1,171
– – ﹤0.01% 4362
2025
Q4 		$3.4K Hold
1,171
– – ﹤0.01% 4376
2025
Q3 		$1.69K Sell
1,171
-9
-0.8% -$9 ﹤0.01% 4552
2025
Q2 		$956 Sell
1,180
-12
-1% -$10 ﹤0.01% 4574
2025
Q1 		$915 Buy
1,192
+1,128
+1,763% +$1.05K ﹤0.01% 4539
2024
Q4 		$82 Hold
64
– – ﹤0.01% 4718
2024
Q3 		$132 Hold
64
– – ﹤0.01% 4707
2024
Q2 		$244 Buy
+64
New +$260 ﹤0.01% 4635

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PNC Financial Services Group's PRLD Position: Q1 2026 in Review

PNC Financial Services Group held its Prelude Therapeutics (PRLD) position steady in Q1 2026 at 1,171 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #4362.

PNC Financial Services Group first reported a position in PRLD in Q2 2024 and has held it in 8 quarters since. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • PNC Financial Services Group held 1,171 shares of Prelude Therapeutics worth $4K as of Q1 2026.
  • PNC Financial Services Group left its Prelude Therapeutics share count unchanged in Q1 2026.
  • Prelude Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4362 holding.
  • PNC Financial Services Group first reported a position in Prelude Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.